

Aug-30-99 17:03 From:HBSR
K:\CEUNEK\DUK\96\PA3\AAFA
CAE \$1
DEB/CAE/smc
08/30/99

17818619540

T-105 P.06/07 F-593

PATENT APPLICATION
Attorney's Docket No. DUK96-03pA3
Expedited Procedure under 37 C.F.R. 1.116
Examining Group: 1654

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

#25

PLUNKETT
10/8/99
(1/2)

Applicants: Jonathan S. Stamler and Andrew J. Gow

Serial No.: 08/796,164

Group Art Unit: 1654

Filed: February 6, 1997

Examiner: B. Celsa

For: Modified Hemoglobins, Including Nitrosylhemoglobins, and Uses Therefor

OK TO
enter
ex Celsa
10/26/99

<p align="center">CERTIFICATE OF FACSIMILE TRANSMISSION I hereby certify that this correspondence is being facsimile transmitted to the United States Patent and Trademark Office on <u>August 30, 1999</u> Date <u>Susan M. Cullen</u> Signature <u>Susan M. Cullen</u> Typed or printed name of person signing certificate</p>

AMENDMENT AFTER FINAL REJECTION UNDER 37 C.F.R. 1.116

Box AF
Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

This Amendment After Final Rejection is being filed in response to the Final Office Action mailed from the U.S. Patent and Trademark Office on March 30, 1999 in the above-identified application.

A two-month extension of time and a Notice of Appeal from the Final Office Action dated March 30, 1999, with appropriate fees, are being filed concurrently.

Please amend the application as follows:

In the Claims

Please cancel Claims 30-32 without prejudice to their prosecution in any related application.